RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.